196; Text count: 3998; Total number of Figures 7, and Reference count: 40 Scientific Category: Lymphoid Neoplasia Abstract Proteasome inhibitors have demonstrated that targeting protein degradation is effective therapy in multiple myeloma (MM). Here we show that deubiquitylating enzymes (DUBs) USP14 and UCHL5 are more highly expressed in MM cells than in normal plasma cells. USP14 and UCHL5 siRNA knockdown decrease MM cell viability. A novel 19S regulatory particle inhibitor b-AP15 selectively blocks deubiquitylating activity of USP14 and UCHL5 without inhibiting proteasome activity. b-AP15 decreases viability in MM cell lines and patient MM cells. Moreover, b-AP15 inhibits proliferation of MM cells even in the presence of bone marrow stroma cells and overcomes bortezomibresistance. Anti-MM activity of b-AP15 is associated with growth arrest via downregulation of CDC25C, CDC2 and cyclin-B1 as well as induction of caspasedependent apoptosis and activation of unfolded protein response. In vivo studies using distinct human MM xenograft models show that b-AP15 is well tolerated, inhibits tumor growth, and prolongs survival. Combining b-AP15 with SAHA, lenalidomide, or dexamethasone induces synergistic anti-MM activity. Our preclinical data showing efficacy of b-AP15 in MM disease models validates targeting DUBs in the ubiquitin proteasomal cascade to overcome proteasome inhibitor resistance, and provides the framework for clinical evaluation of USP14/UCHL5 inhibitors to improve patient outcome in MM.
Key Points
(1) Deubiquitylating enzymes USP14 and UCHL5 are involved in the tumorigenesis of MM.
(2) b-AP 15 is a specific USP14 and UCHL5 inhibitor, which blocks growth and induces apoptosis in MM cells.
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Introduction
The ubiquitin proteasome pathway (UPP) is a validated therapeutic target in multiple myeloma (MM), evidenced by the FDA approval of bortezomib and carfilzomib. 1, 2 Recent studies have focused on targeting enzymes modulating protein ubiquitin conjugation/deconjugation upstream of the proteasome rather than the proteasome itself, with the goal of producing more specific, potent, and less toxic therapies targeting UPP. Importantly, many human diseases are linked to dysfunction of ubiquitin ligases and/or DUBs, suggesting that inhibitors of ubiquitylating or DUB enzymes represent a potential therapeutic strategy. 3, 4 The human genome encodes approximately 100 putative DUBs, which are classified into five families: the USP (the ubiquitin-specific processing protease), UCH (the ubiquitin C-terminal hydrolyase), OTU (the ovarian tumor), MJD (the Josephin domain) and JAMM (the Jab1/Mov34 metalloenzyme) families. 5, 6 Importantly, first four families are cysteine proteases, while the fifth family are metalloproteases, and to date USP and UCH are the best characterized families. 7 DUBs play a central role in regulating cellular processes, such as cell growth, proliferation, apoptosis, DNA repair, kinase activation and transcription. 8, 9 In mammalian cells, three DUBs are associated with the proteasome: USP14, UCHL5/Uch37, and Rpn11. 6, [10] [11] [12] Both USP14 and UCHL5 reversibly associate with 19S regulatory particle, whereas Rpn11 is an intrinsic subunit of the proteasome lid subcomplex of 19S regulatory particle, therefore modulating their functions may affect the proteasomal uptake of protein substrate for degradation. These DUBs have also been implicated in cancer. Screening for genetic abnormalities using retroviral expression libraries and 3T3 focus formation assay shows involvement of USP14 in ovarian carcinogenesis. 13 A recent study shows that USP14 is highly expressed in colorectal cancer and correlates with pathological stage, as well as liver and lymph node metastases. 14 
Deubiquitylation of CXCR4 by USP14 is also crucial for
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From both CXCR4 degradation and chemotaxis. 15 UCLH5, like USP14, plays an important role in regulating oncogenic signaling. 16 For example, transforming growth factor-β (TGF-β) is a critical regulator of cell proliferation, differentiation, and tumor pathogenesis; and UCHL5 regulates TGF-β/Smad signaling by binding to intracellular Smad transcription factors, thereby allowing for deubiquitylation and stabilization of the TGF-receptor. 17 UCHL5 /Rpn13 complex also regulates NF-κB signaling pathway via interaction with I-κB. 18 Additionally, Knockdown of UCHL5 induces apoptosis, whereas overexpression of UCHL5 promotes cell proliferation in A549 cells. Finally, the clinical significance of UCHL5 was demonstrated in a recent analysis of tumor specimens from 111 patients with esophageal squamous cell carcinoma (ESCC), showing a direct correlation between the elevated expression of UCHL5 and lymph nodes metastasis. 19 A recent study described a small molecule inhibitor of USP14 and UCHL5. 20 In contrast to the proteasome inhibitors, b-AP15 blocks the deubiquitylating activity of 19S regulatory particle-associated USP14 and UCHL5 without affecting proteolytic activities of the 20S core particle. 20 Interestingly, b-AP15 triggers cancer cell apoptosis regardless of TP53 status and BCL2 expression level, and inhibits tumor growth and metastasis in vivo. 21 Given the therapeutic success of proteasome inhibition in MM, we here attempted to examine whether b-AP15 blockade of USP14 and UCHL5 had anti-MM activity. Our in vitro and in vivo studies suggest that targeting DUBs can overcome proteasome inhibitor resistance, providing the basis for their clinical evaluation.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Human MM cell lines MM.1S, MM.1R, KMS-11, ARP-1, RPMI 8226, DOX40, LR5, ANBL-6 (ANBL6.WT) and ANBL-6-bortezomibresistant (ANBL-6.BR), and solid tumor cell lines COLO320, LS174, or SHSY5Y, as well as peripheral blood mononuclear cells (PBMCs) from normal healthy donors, were cultured in RPMI-1640 medium supplemented with complete medium [10% FBS (fetal bovine serum), 100 units/mL penicillin, 100 µg/mL streptomycin, and 2mM L-glutamine] at 37 °C and 5% CO2. Solid tumor cell lines DLD-1, 7860, and U2OS cells were cultured in DMEM medium supplemented with complete medium. Patient MM cells and bone marrow stroma cells (BMSCs) were prepared as described previously. 22 Informed consent was obtained from all patients, in accordance with the Helsinki protocol. Drug sources: b-AP15 was provided by Vivolux AB, Uppsala Science Park, Uppsala, Sweden; lenalidomide, bortezomib, and SAHA were purchased from Selleck Chemicals LLC, Houston, TX; and Dex was obtained from Calbiochem, CA.
Materials and Methods

Cell Culture and reagents
Western Blotting Cell lysis was prepared followed by SDS-PAGE, transferring and blocking as described previously. 22 Immunoblotting was performed using antibodies (Abs) against PARP (BD Bioscience Pharmingen, San Diego, CA), caspase-8, caspase-9, caspase-3, cyclinB1, Cyclin E1, Cyclin D1, CDC25C, CDC2, p21, CHOP (Cell Signaling, Beverly, MA), USP14 (Bethyl labs), or UCHL5, p-eIF2α, (Abcam), and XBP1 (Santa cruz), p-IREα (Thermo Scientific). Blots were then developed by enhanced chemiluminescence (ECL; Amersham, Arlington Heights, IL). (Amaxa Biosystems, Cologne, Germany). Cells were harvested 24h post transfection, followed by analysis using both immunoblotting and cell viability assay. Cytotoxicity and cell migration assays Cell viability in MM cell lines, patient MM cells, and normal PBMCs was assessed as described previously. 23 Migration was performed using 24-well transwell plates (Millipore, MA) in the presence of 10% FBS or Stromal-derived factor-1 (SDF-1), and migrating cells were quantified by measuring the intensity of fluorescence. 22 Apoptosis and cell cycle analysis MM.1S cells were treated with vehicle or b-AP15 (100 nM) for 24h and then stained with Annexin V-FITC/ propidium iodide (BD Biosciences, Clontech, CA), followed by quantification of apoptotic cells using FACSCalibur (BD Bio-sciences). Caspase-8 and 9 fluorometric assay kit (Enzo Life Sciences, Farmingdale, NY) was utilized to measure caspase activity. Cell cycle analysis was performed as described previously. 21
Transient transfection
Ub-VS labeling
Human plasmacytoma xenograft models All experiments involving animals
were approved by an institutional Animal Care and Use Committee. The subcutaneous MM.1S mouse xenograft model and the disseminated KMS-11 xenograft model were performed as previously described. 23, 24 b-AP15 (4 mg/kg) was injected on a 14 Immunostaining Tumor sections from mice were stained with antibodies.
Immunostained tissues were imaged using microscopy (Zeiss AxioImager M1 Microscope, Oberkochen, Germany). 21, 23 Statistical analysis A Student's t-test was utilized to determine a significant difference, and P < 0.05 was considered statistically significant. The mice survival was determined using the Graphpad Prism software (Graphpad Software, La Jolla, CA). Fig 1B) .
Importantly, USP14 and UCHL5 expression is higher in MM cell lines than in normal PBMCs ( Fig 1B) . Similarly, immunostaining of BM biopsies from MM patients and normal healthy donors showed that USP14 and UCHL5 are highly expressed in MM cells; in contrast, normal plasma cells lack detectable USP14 and UCHL5 expression ( Fig 1C and Suppl. Fig 1) .
We next assessed the functional significance of USP14 and UCHL5 in MM cells using siRNA strategy. USP14 and UCHL5 protein expression was markedly knocked down by USP14 and UCHL5 smart pool siRNAs compared with scrambled siRNA, as quantified by densitometric analysis (Fig 1D) . Transfection of MM.1S cells with either USP14 siRNA or UCHL5 siRNA alone triggered cell death compared with scramble-siRNA-transfected cells ( Fig 1E) . Importantly, simultaneous knockdown of USP14 and UCHL5 induced significantly greater cell death versus cells transfected with siRNA against either USP14 or UCHL5 ( Fig 1E) . Together, these data suggest a growthpromoting role of USP14 and UCHL5 in MM cells, and provide a rationale for potential therapeutic targeting of USP14 and UCHL5 in MM.
b-AP15 inhibits USP14 and UCHL5 activity in MM cells
It is well established that inhibition of DUBs or proteasome causes accumulation of ubiquitinated proteins 26 .
Our result showed that treatment of MM.1S cells with b-AP15 (100 nM), like bortezomib, induced time-dependent accumulation of ubiquitinated proteins (Fig 2A) . The disappearance of b-AP15 activity on poly-ubiquitination at later time points might be due to the onset of cell-cycle arrest and apoptosis. Additionally, b-AP15 inhibited the activity of both USP14 and UCHL5 as evident by decreased Ub-VS labeling when compared to mock vehicle-treated MM.1S cells ( Fig 2B) . While b-AP15 blocks the deubiquitylating activity of USP14 and UCHL5, it does not inhibit proteasome activity. Specifically, treatment of MM.1S cells with b-AP15 for 3h did not affect chymotrypsin-like (CT-L), trypsin-like (T-L), or caspase-like (C-L) proteasome activities ( Fig 2C) . Proteasome inhibitor bortezomib served as a control for CT-L activity inhibitor ( Fig 2C) . To further confirm b-AP15 specific activity against USP14 and UCHL5, we examined the effect of b-AP15 on other DUBs such as USP7 or UCHL3 using additional MM cell lines RPMI-8226 and KMS11. No inhibition of total DUB or proteasome proteolytic activity in b-AP15-treated MM cells was observed ( Supplementary Fig 2A and Fig 2B) . In addition, b-AP15 significantly inhibited both USP14 and UCHL5, whereas no inhibition of USP7 or UCHL3 was noted ( Supplementary Fig 2C and Fig 2D) . Furthermore, no inhibition in HA- Fig 2E) .
UbVS binding in protein lysates from b-AP15-treated MM cells (Supplementary
Together, our resultes show that b-AP15 potently inhibits USP14 and UCHL5 without affecting enzymatic activity of other DUBs.
Examination of the activity of b-AP15 and bortezomib on a neuronal cell survival
protease HtrA2/Omi 22 showed that bortezomib inhibited HtrA2/Omi while no significant inhibition of HtrA2/omi was noted in response to b-AP15 treatment ( Fig 2D) .
Anti-MM activity of b-AP15 in vitro Various human MM cell lines including drug
resistant cell lines were treated with b-AP15 for 48h, followed by assessment for cell viability. A significant concentration-dependent decrease in viability of all MM cell lines was observed in response to treatment with b-AP15 ( Fig 3A) . b-AP15 showed similar IC 50 in drug-resistant derived as in parental isogenic cell lines. Interestingly, a potent anti-tumor activity of b-AP15 was also observed in solid tumor cell lines ( Supplementary   Fig 3) . Additionally, b-AP15 significantly decreased the cell viability of all primary MM cells from patients including those relapsed after multiple prior therapies with lenalidomide, Dex, or bortezomib ( Fig 3B) . Importantly, b-AP15 at the IC 50 for MM cells does not significantly affect the viability of normal PBMCs ( Fig 3C) .
BMSCs confer cytoprotective effect to MM cells. In our result, significant inhibition of BMSCs-induced proliferation of MM.1S cells was noted in response to b-AP15 treatment ( Fig 3D) .
SDF-1 binds to G-protein-coupled CXCR4, the known substrate of USP14, 15 and importantly, CXCR4 is implicated in MM metastasis. 25 We therefore examined serum or SDF-1-induced MM cell migration. Serum or SDF-1 alone increased MM.1S cell migration; conversely, b-AP15 inhibits serum or SDF-1-dependent migration ( Fig 3E) .
These cells were >95% viable prior to and after performing the migration assay.
b-AP15 induces apoptosis and cell cycle arrest in MM cells To further
understand the mechanism of action underlying b-AP15-induced MM cell death, MM.1S cells were treated with b-AP15 (100 nM) for 12h, and then stained with Annexin V/PI. b-AP15 triggered a significant increase in both early (Annexin V+/PI−) and late (Annexin V+/PI+) apoptotic cell populations ( Fig 4A) . Moreover, b-AP15 markedly increased the cleavage of PARP, a hallmark of apoptosis. We next examined whether b-AP15 affects the intrinsic (via caspase-9) and extrinsic (via caspase-8) apoptotic signaling pathways.
Our data show that b-AP15 activates caspase 8, caspase-9, followed by activation of caspase-3 ( Fig 4B) . Additionally, b-AP15 induced Caspase 8 and caspase-9 enzymatic activity, as determined using ELISA ( Fig 4C) . Importantly, blockade of caspases by pancaspase inhibitor significantly attenuated b-AP15-triggered MM cell death ( Fig 4D) .
Recent studies indicate that DUBs play a pivotal role in the regulation of cell cycle 7 . We therefore examined the effect of b-AP15 on cell cycle profile using two distinct MM cell lines, MM.1S and KMS-11. b-AP15 induced significant G 2 /M phase growth arrest in both cell lines ( Fig 4E) . In accordance with these findings, b-AP15 treatment decreased G 2 /M phase cell cycle regulatory proteins cdc25c and its down For personal use only. on September 14, 2017. by guest www.bloodjournal.org From stream protein cdc2, as well as cyclin B1 ( Fig 4F) . Additionally, we also examined the effect b-AP15 on G 1 /S phase marker proteins including cyclin E1, cyclin D1, and p21.
Results showed b-AP15 induced p21 without any significant change in cyclin E1 and cyclin D1 ( Supplementary Fig 4A) .
b-AP15 triggers endoplasmic reticulum (ER) stress response signaling in MM cells Accumulation of ubiquitylated proteins (misfolded/unfolded) induces UPR and apoptosis. 26 A head-to-head experiment comparing the effect of b-AP15 and bortezomib on ER Stress response showed that treatment of MM.1S with b-AP15 or bortezomib activates PERK and IRE1-mediated ER stress signaling, evidenced by significant induction of p-IREα and p-eIF2α ( Fig 4G) . XBP-1 plays an important role in MM pathogenesis and drug resistance. 27 Interestingly, although we observed the induction of XBP-1(s) with bortezomib treatment, no induction of XBP-1(s) was detected with treatment of b-AP15 ( Fig 4H) . We did not observe detectable active form of ATF6 in both b-AP15 and bortezomib treatment cells (data not shown). Additionally, b-AP15 and bortezomib triggered induction of CHOP ( Fig 4E) . We next compared the effect of b-AP15 versus bortezomib on induced ER stress response signaling using ANBL6.WT and ANBL6.BR cell lines. b-AP15 upregulated p-eIF2α and CHOP in both ANBL6.WT and ANBL6.BR cells ( Supplementary Fig 4B) . Bortezomib-induced cytotoxicity in ANBL6.WT correlated with induction of p-eIF2α and CHOP. In contrast, treatment of ANBL6.BR with IC 50 for ANBL6.WT triggered no significant decrease in viability, but upregulated p-eIF2α without altering CHOP expression ( Supplementary Fig 4B) . No basal level expression change in p-eIF2α and CHOP expression was noted in ANBL6.WT versus ANBL6.BR cell line.
Anti-MM activity of b-AP15 in MM xenograft mouse models
Having shown that b-AP15 induced apoptosis in MM cells in vitro, we next examined the in vivo efficacy For personal use only. on September 14, 2017. by guest www.bloodjournal.org From of b-AP15 using two distinct MM xenograft mouse models. A marked reduction in tumor growth as well as prolongation of survival was noted in b-AP15-treated mice versus mice receiving vehicle alone (Fig 5A and 5B) . Mechanistic study using immunohistochemical (IHC) staining showed a decrease in proliferation marker Ki67 and an increase in the number of caspase-3 cleavage-positive cells in tumors excised from mice receiving b-AP15 ( Fig 5C) . Vascular endothelial growth factor (VEGF) and VEGFR2 play a central role in tumor angiogenesis, and we therefore examined the expression of VEGF and VEGFR2 as well as other tumor growth-associated angiogenesis markers LYVE1 and CD-31 in control-versus b-AP15-treated mice tumors. A marked reduction in VEGF, VEGFR2, LYVE1 and CD-31 expression was observed in tumors from b-AP15-treated mice versus mice receiving vehicle alone ( Fig 5C) . Moreover, the doses of b-AP15 administered were well tolerated by mice, since no significant weight loss was noted in the study ( Fig 5D) . As seen in Figure 5E , b-AP15-treated mice retained normal creatinine, hemoglobin, and bilirubin levels.
In order to further validate the in vivo anti-MM activity of b-AP15, we utilized a KMS-11 disseminated MM xenograft mouse model. Treatment KMS-11 bearing mice with b-AP15 significantly decreased the tumor burden of the mice ( Fig 6A) ; of note, only 2 of 8 mice receiving b-AP15 treatment showed signs of disease. As shown in Figure   6B , a significant decrease in bioluminescence intensity was observed in b-AP15-vs.
vehicle-treated mice at day 32. Furthermore, b-AP15 treatment dramatically prolonged survival, with the median survival extending from 55 to > 93 days ( Fig 6C) . IHC analysis in tumor tissues showed that b-AP15 enhanced ubiquitination in tumor cells in vivo.
Specifically, the K-48-linked ubiquitination was clearly evident in tumor sections from b-AP15-treated mice vs. the vehicle control group (Fig. 6D ). Taken together, our findings using two distinct murine xenograft models of human MM show potent in vivo anti-tumor activity of b-AP15 at doses that are well tolerated. 
Discussion
Recent reports have identified several DUBs 7,28,29 and elucidation of their structures and functional roles in tumorigenesis has provided the impetus for validating them as novel therapeutic targets in cancer. [30] [31] [32] Although, USP14 and UCHL5 have been implicated in the tumorigenesis and progression of colorectal and ESCC, 14, 19 their role in MM is undefined. Consistent with previous studies, 15, 16, 21 we found that USP14 and UCHL5 are highly expressed in MM cells versus normal plasma cells and PBMCs, suggesting a role of USP14 and UCHL5 in MM pathogenesis. Importantly, knockdown of USP14 and UCHL5 decreased MM cell viability, indicating involvement of USP14 and UCHL5 in MM growth and survival.
A recent study identified b-AP15, a novel small molecule inhibitor of USP14 and UCHL5. 21 We here examined the anti-MM activity of b-AP15 using our in vitro and in vivo models of MM. b-AP15 induced a marked increase in ubiquitylated proteins and inhibited the labeling of USP14 and UCHL5 with HA-Ub-VS. No difference in the labeling of other DUBs with Ub-VS probe was observed, confirming that b-AP15 is a selective DUB inhibitor. Additionally, previous study found that treatment with b-AP15 achieved the free ubiquitin pool decreases to a similar extent as with bortezomib in colon carcinoma and melanoma cells; and overexpression of K48 and WT ubiquitin chains only slightly changed the apoptotic activity versus control. 21 These data suggest that although depletion of the free ubiquitin pool is likely to be a factor, overexpression of ubiquitin does not appear to reverse this process. 21 Moreover, b-AP15 triggered no alteration in the proteolytic activities of the proteasome and total DUB activity. Together, these data demonstrate that b-AP15 targets the deubiquitylating function of USP14 and UCHL5 in the cellular environment.
Peripheral neuropathy associated with bortezomib therapy is partly due to blockade of neuronal cell survival protease HtrA2/Omi. 2 In the present study, we found We next characterized the mechanism underlying anti-MM activity of b-AP15.
We showed that b-AP15 decreased viability of MM cell lines and primary patient tumor cells, without markedly affecting normal PBMCs viability, suggesting selective anti-MM activity and a favorable therapeutic index for b-AP15. The difference of IC 50 of b-AP15 in MM cell lines may be due to the genetic heterogeneity characteristics of MM. 23, 33 Moreover, b-AP15 decreased the viability of both ANBL-6.WT and ANBL-6.BR MM cells, confirming the ability of b-AP15 to overcome bortezomib resistance. Importantly, we found similar responses to b-AP15 in tumor cells from patients where MM is resistant to therapies such as bortezomib, lenalidomide or Dex.
It is well established that BMSCs confer resistance to anti-MM agents via celladhesion mediated drug resistance (CAM-DR). In our study, b-AP15 inhibits BMSCinduced proliferation of MM.1S cells in a concentration-dependent fashion, suggesting that b-AP15 has the ability to overcome CAM-DR.
DUBs play a role in diverse signaling pathways including apoptosis and cell cycle progression. 5, 9, 34 Cell cycle is tightly regulated by numerous cyclins, cyclin-dependent kinases and checkpoint proteins, which in turn, are degraded in timely manner by ubiquitin proteasome signaling pathway. For example, CDC25C, dephosphorylates cyclin B-bound CDC2 and triggers entry into mitosis. 35 Moreover, CDC25C and cyclinB are degraded through proteasome-mediated degradation pathway. 9, 36, 37 Importantly, prior studies have established that p21 mediates growth arrest in different cell-cycle phases. Activation of p21 triggers inhibition of CDK1-cyclinB1 kinase activity, which in turn, blocks the progression of cells through G2 or G2/M. 38 Our results show that b-AP15 induces G 2 /M phase cell cycle arrests, downregulates CDC25C, CDC2 and CyclinB1, For personal use only. on September 14, 2017. by guest www.bloodjournal.org From and upregulates p21 in MM cells. The mechanism of b-AP15-mediated depletion of cyclin B1, CDC2, and CDC25C is unclear, but it is likely due to enhanced degradation of proteasome regulated cyclins.
Our mechanistic study shows that b-AP15 triggers apoptosis in MM cells via activation of caspases. Furthermore, addition of a pan-caspase inhibitor attenuates b-AP15-induced MM cell death. Moreover, we found that both b-AP15-and bortezomib triggered UPR, evidenced by induction of p-IREα, p-eIF2α and CHOP. We did not observe detectable active form of ATF6 in both b-AP15 and bortezomib treatment cells.
However, in contrast to bortezomib, b-AP15 did not affect XBP-1 splicing. It is possible that b-AP15 activates IRE1/JNK pathway instead of IRE1/XBP-1 pathway, 39 and this remains to be further examined. Nonetheless, these data show that both b-AP15 and bortezomib trigger ER stress signaling in MM.1S cells, albeit with some distinction.
Bortezomib-induced cytotoxicity in ANBL6.WT correlated with induction of p-eIF2a and CHOP. In contrast, treatment of ANBL6.BR with IC 50 of bortezomib for ANBL6.WT triggered no significant decrease in viability, but upregulated p-eIF2a without altering CHOP ( Supplementary Fig 4) . These data suggest that bortezomib triggered a weaker UPR in ANBL6.BR compared with ANBL6.WT cells. Our data is consistent with a previous report showing that a weak UPR induction can be resolved by induction of p-eIF2α via protein synthesis inhibition; this may prevent both CHOP upreulation and apoptosis. 40 Together, our data suggest that b-AP15-triggered apoptosis in MM cells occurs in a caspase-dependent manner and involves induction of UPR signaling pathways.
In addition to our in vitro studies, we also examined anti-MM activity of b-AP15 in vivo. A marked growth inhibitory effect of b-AP15 was observed in two distinct human MM xenograft mouse models. Our data shows that b-AP15 is well tolerated, inhibits 
